title: Comparison of clinicopathologic characteristics of urothelial carcinoma between patients after renal transplantation and on dialysis.
abstract: BACKGROUND
  Urothelial carcinoma (UC) is a common complication after renal replacement therapy (RRT) among Chinese end-stage renal disease (ESRD) patients. It is unclear whether there are any differences in the clinicopathologic characteristics of UC between renal transplantation (RT) and dialysis patients; such differences could impact RRT modality selection.
  
  
  METHODS
  We retrospectively reviewed clinicopathologic data for 27 RT patients and 40 dialysis patients who were diagnosed with UC in our center to explore differences in the clinicopathologic characteristics of UC and prognoses between the two groups.
  
  
  RESULTS
  The median follow-up period was 92 months (2-137) for the RT group and 71 months (18-155) for the dialysis group. The demographic and baseline data showed no significant differences between the two groups. Upper urinary tract UC (UUC) occurred more frequently in the RT group (22 UUCs in 39 UCs), whereas bladder UC (BUC) predominated in the dialysis group (33 BUCs in 49 UCs) (P=0.025). The pathologic grading in the RT group was significantly higher than that in the dialysis group (P=0.046 for WHO1973 grading, P=0.026 for WHO2004 grading), whereas the difference in tumor stage was not significant (P=0.089). The RT group manifested a higher recurrence rate than the dialysis group (P=0.024). However, the overall and cancer-specific survival rates between the two groups were not significantly different (P=0.239 and P=0.818, respectively).
  
  
  CONCLUSIONS
  Certain traits of UC, including tumor site, pathologic grading, and recurrence-free survival, were notably different between RT and dialysis patients, but the overall and cancer-specific survival rates were similar.
authors.affiliation: 1 Institute of Urology, Peking University, Beijing, People's Republic of China. 2 Department of Urology, Peking University First Hospital, Beijing, People's Republic of China. 3 National Urological Cancer Center, Beijing, People's Republic of China. 4 Address correspondence to: Cheng Shen, M.D., Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, NO.8 Xi Shi Ku St., West District, Beijing, People's Republic of China,100034; Wen-ke Han, M.D., Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, NO.8 Xi Shi Ku St., West District, Beijing, People's Republic of China,100034.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Cheng
authors.initials: C
authors.lastname: Shen
authors.forename: Wen-ke
authors.initials: WK
authors.lastname: Han
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality; D002681:China; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis* / Q000401:mortality; D011379:Prognosis; D006435:Renal Dialysis; D012189:Retrospective Studies; D016019:Survival Analysis; D014571:Urologic Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality